Pregabalin controlled-release - Mapi Pharma

Drug Profile

Pregabalin controlled-release - Mapi Pharma

Alternative Names: Pregabalin ER - Mapi Pharma; Pregabalin extended-release - Mapi Pharma

Latest Information Update: 07 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mapi Pharma
  • Developer Jiangsu Nhwa Pharmaceutical; Mapi Pharma
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Neuroprotectants; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Neuropathic pain

Most Recent Events

  • 27 Oct 2016 Chemical structure information added
  • 24 Oct 2016 Phase-II clinical trials in Neuropathic pain in China (PO) before October 2016 (Mapi Pharma Form F-1, January 2016 and Mapi Pharma pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top